Polaryx Therapeutics, Inc. PLYX
- Market cap
- $106.7M
- P/E
- 0.0×
Follow PLYX
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
Low Price | ||
| — | — | — | — | — | — | — | — | — | — | High Price | |||
| — | — | — | — | — | — | — | — | 11 | 11 |
Employees
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | (30) | (9) |
EBT
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | — | — | — | — | (30) | (9) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.89) | (0.19) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.08) | (0.09) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.08) | (0.09) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.14 | 0.10 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | 34 | 45 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | (3) | (4) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | (3) | (4) |
FCF
|
|||
| — | — | — | — | — | — | — | — | 5 | 5 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | (5) | (5) |
Net Debt
|
|||
| — | — | — | — | — | — | — | — | 5 | 5 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (176.68%) |
ROA
|
|||
| — | — | — | — | — | — | — | — | (2,989.01%) | 0.00% |
ROIC
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (193.70%) |
ROE
|
|||
Polaryx Therapeutics, Inc. (PLYX) key facts
- Polaryx Therapeutics, Inc. reported a net loss of $9.0 million, or a loss of $0.19 per share, for fiscal 2025.
- As of September 25, 2026, PLYX traded at $2.09, a market capitalization of $106.7 million.
- Return on equity was −193.7% and debt-to-equity 0.00.
Polaryx Therapeutics, Inc. (PLYX) Latest News
25 Aug
Polaryx Therapeutics advances operational readiness for SOTERIA Phase 2 Basket Trial. Phase 2 trial operational progress signals major clinical development step with direct effect on future pipeline and market trajectory.
28 May
Polaryx Therapeutics closed a $10 million private placement equity financing. The proceeds will fund the launch of the SOTERIA Phase 2 basket trial. Securing $10 million directly funds a Phase 2 trial launch and bolsters the company's clinical development and cash runway.
21 Apr
Polaryx Therapeutics received U.S. FDA Fast Track Designations for all four indications to be evaluated in the SOTERIA Basket Trial. FDA Fast Track designations for all four indications accelerate regulatory timelines and strengthen Polaryx's development and commercialization path.
17 Mar
Polaryx Therapeutics receives FDA Fast Track Designation for PLX-200 to treat Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease). FDA Fast Track Designation accelerates review and boosts development prospects for PLX-200.
17 Feb
Polaryx Therapeutics, Inc. (PLYX) has selected a contract research organization to run its SOTERIA Phase 2 basket trial. CRO selection advances the SOTERIA Phase 2 trial and supports pipeline progress without ensuring regulatory or commercial success.
10 Feb
Polaryx Therapeutics announced key pre-clinical data related to SOTERIA at the 22nd Annual WORLDSymposium. Pre-clinical data release advances pipeline visibility but remains early-stage without immediate commercial effects.
4 Feb
Polaryx Therapeutics plans to present late-breaker data on Soteria ahead of its trial. Upcoming data presentation may moderately shape trial expectations and investor views on product progress.
3 Feb
Polaryx Therapeutics will present late-breaker data related to SOTERIA at the 22nd Annual WORLDSymposium as it prepares for the SOTERIA trial launch. Late-breaker data presentation and SOTERIA trial launch preparation indicate substantial clinical development progress likely to affect company trajectory.
2 Feb
Polaryx Therapeutics announces direct listing on Nasdaq with shares to begin trading under the symbol PLYX. Direct Nasdaq listing provides major increase in visibility, liquidity and capital access for the company.
30 Jan
Polaryx Therapeutics, Inc. (PLYX) receives approval to list its common stock on Nasdaq. Nasdaq listing approval provides major access to capital markets and boosts stock liquidity and visibility.